Zobrazeno 1 - 10
of 102
pro vyhledávání: '"Kenneth I. Kaitin"'
Publikováno v:
Frontiers in Pharmacology, Vol 10 (2019)
A host of challenges confront healthcare authorities worldwide. Topping the list is the demand for innovative new medicines to treat a range of both infectious and non-communicable diseases, while containing spiraling healthcare costs. The challenge
Externí odkaz:
https://doaj.org/article/1ff862d7a5794923a3305f12e045b1b0
Publikováno v:
Drug Discovery Today. 28(3)
Central nervous system (CNS) drug discovery suffers from high attrition rates; translational neuroscience approaches aiming to reduce these high rates include the use of brain imaging technologies. However, there is a need to better understand what m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ff99d6a2f9efafedd3c7dfbd17d4d04
https://doi.org/10.1016/j.drudis.2023.103485
https://doi.org/10.1016/j.drudis.2023.103485
Publikováno v:
Nature Reviews Drug Discovery. 22:344-345
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7fb51a09f61d8e5fbf2232ca8b7f0fd1
https://doi.org/10.1038/d41573-023-00058-0
https://doi.org/10.1038/d41573-023-00058-0
Publikováno v:
Nature Reviews Drug Discovery. 22:12-13
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::82b5ddc8c4f50a4129f63b422bebe1aa
https://doi.org/10.1038/d41573-022-00167-2
https://doi.org/10.1038/d41573-022-00167-2
Autor:
Marisha E. Palm, Harry P. Selker, Theodora Cohen, Kenneth I. Kaitin, Kay Larholt, Mark Trusheim, Gigi Hirsch
Publikováno v:
Broadly Engaged Team Science in Clinical and Translational Research ISBN: 9783030830274
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::05aaf4cb034368b7b48693ea7408e32f
https://doi.org/10.1007/978-3-030-83028-1_6
https://doi.org/10.1007/978-3-030-83028-1_6
Autor:
Kenneth I. Kaitin, Kenneth Getz
Publikováno v:
Broadly Engaged Team Science in Clinical and Translational Research ISBN: 9783030830274
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6407201ae2172db3823aabaa264af3c0
https://doi.org/10.1007/978-3-030-83028-1_7
https://doi.org/10.1007/978-3-030-83028-1_7
Autor:
Newell E. McElwee, Peter K. Honig, Norman Stockbridge, Harry P. Selker, Hans-Georg Eichler, Kenneth I. Kaitin, Theodora Cohen, John K. Erban, Vicki L. Seyfert-Margolis, Willard H. Dere, Kenneth A. Oye, Ralph B. D'Agostino
Publikováno v:
Clinical Pharmacology and Therapeutics
Efficacy trials, designed to gain regulatory marketing approval, evaluate drugs in optimally selected patients under advantageous conditions for relatively short time periods. Effectiveness trials, designed to evaluate use in usual practice, assess t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10e88cd3eb51ccd5afd622e80251782b
http://europepmc.org/articles/PMC6422692
http://europepmc.org/articles/PMC6422692
Autor:
Kenneth A. Oye, Kenneth I. Kaitin, Newell E. McElwee, Heather C. Kaplan, Ralph B. D'Agostino, Richard L. Kravitz, Kay Larholt, Hans Georg Eichler, Willard H. Dere, Chandra Ramanathan, S. Nassir Ghaemi, Mark R. Trusheim, Eleanor M. Perfetto, Vicki L. Seyfert-Margolis, Marisha E. Palm, Theodora Cohen, Christopher H. Schmid, Peter Honig, Harry P. Selker
Publikováno v:
Clinical pharmacology and therapeutics. 112(2)
Clinicians and patients often try a treatment for an initial period to inform longer-term therapeutic decisions. A more rigorous approach involves N-of-1 trials. In these single-patient crossover trials, typically conducted in patients with chronic c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1354af192cccc8bd0743b15002a21ff5
https://pubmed.ncbi.nlm.nih.gov/34551122
https://pubmed.ncbi.nlm.nih.gov/34551122
Publikováno v:
Therapeutic innovationregulatory science. 55(4)
The last two decades have witnessed the vigorous development of targeted cancer drugs and the potent therapeutic effects of these drugs have been validated by various true and surrogate end points. Overall survival (OS) and progression-free survival
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f6a5ad20fa171008204ec2e2cc6b864
https://pubmed.ncbi.nlm.nih.gov/33683659
https://pubmed.ncbi.nlm.nih.gov/33683659
Autor:
Kenneth I. Kaitin
Publikováno v:
Clinical therapeutics. 41(8)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2dbb5e5c07d0ed8ca87240efae7a3ec0
https://pubmed.ncbi.nlm.nih.gov/31353132
https://pubmed.ncbi.nlm.nih.gov/31353132